Publications 2009 – 2006

| 2016 thru 2014 | 2013 thru 2010 | 2009 | 2008 | 2007 | 2006 | 2005 thru 2001 |



  1. Sasportas LS, Kasmieh R, Wakimoto H, Hingtgen S, van de Water JA, Mohapatra G, Figueiredo JL, Martuza RL, Weissleder R, Shah K. Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy. P Natl Acad Sci U S A. 2009;106(12):4822-7 – PMID: 19264968 – PMCID: PMC2660771
  2. Yoo B, Gredler R, Vozhilla N, Su Z, Chen D, Forcier T, Shah K, Saxena U, Hansen U, Fisher P, Sarkar D. Identification of genes conferring resistance to 5-fluorouracil. P Natl Acad Sci U S A. 2009;106(31):12938-43 – PMID: 19622726 – PMCID: PMC2722317
  3. Wakimoto H, Kesari S, Farrell CJ, Curry WT, Zaupa C, Aghi M, Kuroda T, Stemmer-Rachamimov A, Shah K, Liu TC, Jeyaretna DS, Debasitis J, Pruszak J, Martuza RL, Rabkin SD. Human Glioblastoma-Derived Cancer Stem Cells: Establishment of Invasive Glioma Models and Treatment with Oncolytic Herpes Simplex Virus Vectors.Cancer Res. 2009;69(8):3472-81 – PMID: 19351838 – PMCID: PMC2785462
  4. Piccirillo G M, Binda E, Fiocco R, Vescovi L, Shah K. Brain cancer stem cells. J Mol Med. 2009;:ePub – PMID:19784875
  5. Kumar A, Chung E, Raymond S, van de Water J, Shah K, Fukumura D, Jain R, Bacskai B, Boas D. Feasibility of in vivo imaging of fluorescent proteins using lifetime contrast. Opt Lett. 2009;34(13):2066-8 – PMID:19572001
  6. Shah K. Imaging neural stem cell fate in mouse model of glioma. Curr Protoc Stem Cell Biol. 2009;Chapter 5:Unit5A.1 – PMID: 19306259


  1. Corsten MF, Shah K. Therapeutic stem-cells for cancer treatment: hopes and hurdles in tactical warfare.Lancet Oncol. 2008;9(4):376-84 – PMID: 18374291
  2. Shah K, Hingtgen S, Kasmieh R, Figueiredo JL, Garcia-Garcia E, Martinez-Serrano A, Breakefield X, Weissleder R. Bimodal viral vectors and in vivo imaging reveal the fate of human neural stem cells in experimental glioma model. J Neurosci. 2008;28:4406-13 – PMID: 18434519
  3. Hingtgen S, Ren X, Terwilliger E, Classon M, Weissleder R, Shah K. Targeting multiple pathways in gliomas with stem cell and viral delivered S-TRAIL and Temozolomide. Mol Cancer Ther. 2008;7(11):3575-85 – PMID: 19001440 – PMCID: PMC2748233
  4. Deliolanis NC, Kasmieh R, Wurdinger T, Tannous BA, Shah K, Ntziachristos V. Performance of the red-shifted fluorescent proteins in deep-tissue molecular imaging applications. J Biomed Opt. 2008;13(4):044008 – PMID: 19021336 – PMCID: PMC2749214
  5. Dent P, Yacoub A, Park M, Sarkar D, Shah K, Curiel D, Grant S, Fisher P. Searching for a cure: Gene therapy for glioblastoma. Cancer Biol Ther. 2008;7(9):1335-40 – PMID: 18708757
  6. Yacoub A, Hamed H, Emdad L, Dos Santos W, Gupta P, Broaddus W, Ramakrishnan V, Sarkar D, Shah K, Curiel D, Grant S, Fisher P, Dent P. MDA-7/IL-24 plus radiation enhance survival in animals with intracranial primary human GBM tumors. Cancer Biol Ther. 2008;7:917-33 – PMID: 18376144
  7. Yip S, Shah K.Stem-cell based therapies for brain tumors. Curr Opin Mol Ther. 2008;10:334-42 – PMID: 18683097


  1. Corsten MF, Miranda R, Kasmieh R, Krichevsky AM, Weissleder R, Shah K. MicroRNA-21 Knockdown Disrupts Glioma Growth In vivo and Displays Synergistic Cytotoxicity with Neural Precursor Cell Delivered S-TRAIL in Human Gliomas. Cancer Res. 2007;67(19):8994-9000 – PMID: 17908999
  2. Arwert E, Hingtgen S, Figueiredo JL, Bergquist H, Mahmood U, Weissleder R, Shah K. Visualizing the dynamics of EGFR activity and antiglioma therapies in vivo. Cancer Res. 2007;67 (15):7335-7342 – PMID: 17671203
  3. Kock N, Kasmieh R, Weissleder R, Shah K. Tumor Therapy Mediated by Lentiviral Expression of shBcl-2 and S-TRAIL. Neoplasia. 2007;9(5):435-42 – PMID: 17534449 – PMCID: PMC1877976
  4. Hink M, Shah K, Russinova E, de Vries S, Visser A. Fluorescence Fluctuation Analysis of AtSERK and BRI1 Oligomerization. Biophys J. 2007;:ePub – PMID: 17905839 – PMCID: PMC2186235


  1. Shah K, Breakefield XO. HSV Amplicon Vectors for Cancer Therapy. Curr Gene Ther. 2006;6(3):361-70 – PMID: 16787187